Apr-16-19 Phase 2B GI Safety Results for ATB-346 Published in British Journal of Pharmacology
Mar-29-19 Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
Feb-27-19 Antibe Therapeutics Announces Closing of $5.75 Million Bought Deal Offering
Feb-22-19 Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company
Feb-15-19 Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results
Feb-04-19 Antibe Therapeutics Announces $5 Million Bought Deal Offering
Jan-21-19 Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Dec-19-18 Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises
Nov-30-18 Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018
Nov-27-18 Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Nov-23-18 Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results
Oct-22-18 Antibe Therapeutics Establishes Business Development Advisory Board
Oct-10-18 Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Oct-03-18 Antibe Therapeutics Announces Grant of Restricted Share Units
Sep-05-18 Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
Aug-29-18 Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results
Aug-29-18 Antibe Provides Scientific Report on its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Jul-31-18 Antibe Therapeutics Provides Clinical Development Update on its Lead Drug
Jul-06-18 Antibe Completes Share Issuance in Connection with Citagenix Credit Facility
Jul-03-18 Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346